Biochemistry
Glycogen Metabolism
Storing and mobilizing glucose — glycogenesis, glycogenolysis, and hormonal control
Glycogen metabolism is how animals store and retrieve glucose on demand, packing tens of thousands of sugar molecules into a single branched polymer instead of leaving them loose in the cytosol. Synthesis (glycogenesis) is run by glycogen synthase, which extends α-1,4 chains from the activated donor UDP-glucose on a glycogenin primer; breakdown (glycogenolysis) is run by glycogen phosphorylase, which uses inorganic phosphate to snap off glucose-1-phosphate one residue at a time. The liver stores about 100 g to buffer blood glucose, while skeletal muscle stores about 400 g as a private fuel for contraction. The switch between building and breaking is thrown reciprocally by insulin, glucagon, and epinephrine through the cAMP–PKA and PI3K–Akt cascades. Carl and Gerty Cori mapped the core reactions and shared the 1947 Nobel Prize; defects in the pathway cause the glycogen storage diseases, from von Gierke to McArdle.
- Liver store~100 g (blood-glucose buffer)
- Muscle store~400 g (local ATP only)
- Activated donorUDP-glucose
- Branch spacingα-1,6 every 8–12 residues
- Primer proteinGlycogenin (self-glucosylating)
- Nobel PrizeCarl & Gerty Cori, 1947
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why glycogen metabolism matters
- It keeps the brain fed between meals. The human brain burns roughly 120 g of glucose a day and cannot store its own. Liver glycogen — about 100 g, releasing free glucose through glucose-6-phosphatase — is the fast buffer that holds blood sugar near 5 mM (90 mg/dL) during the hours between eating, before slower gluconeogenesis takes over.
- It powers explosive muscle work. Skeletal muscle holds the largest single pool, roughly 400 g, and burns it locally. Because muscle lacks glucose-6-phosphatase, that glucose never leaves the cell — it feeds glycolysis directly for sprinting, lifting, and the first minutes of any hard effort before fat oxidation ramps up.
- Depletion is why athletes "hit the wall." Muscle glycogen typically lasts 60 to 120 minutes at endurance intensity. Its exhaustion around the 30-km mark of a marathon produces the sudden fatigue runners call bonking, and carbohydrate loading — over-filling stores 50 to 100% above baseline — is the standard countermeasure.
- It explains a whole family of diseases. At least 15 glycogen storage diseases arise from single-enzyme defects: von Gierke (type I, glucose-6-phosphatase), Pompe (type II, lysosomal acid α-glucosidase), Cori (type III, debranching enzyme), McArdle (type V, muscle phosphorylase), and Hers (type VI, liver phosphorylase). Each maps precisely onto one step of the pathway.
- It is the textbook case of hormonal reciprocal control. Insulin, glucagon, and epinephrine flip the same molecular switches in opposite directions — activating synthesis while inhibiting breakdown, or vice versa — through cAMP, protein kinase A, GSK-3, and protein phosphatase 1. It is the model students learn before every other metabolic control circuit.
- It is a validated drug target. Because hepatic glycogenolysis contributes to fasting hyperglycemia in type 2 diabetes, glycogen phosphorylase inhibitors have been pursued as antidiabetic agents, and the enzyme's allosteric AMP site remains a classic case study in structure-based drug design.
How glycogen metabolism works
The molecule. Glycogen is a single, tree-like polymer of glucose. Straight runs are joined by α-1,4 glycosidic bonds, and about every 8 to 12 residues a branch is introduced by an α-1,6 bond. A mature cytosolic granule (a beta particle) can contain on the order of 55,000 glucose units and is built outward from a core protein, glycogenin, that primes the chain by attaching the first ~8 glucoses to one of its own tyrosine residues. The dense branching does two things: it keeps the polymer soluble and osmotically quiet, and it multiplies the number of non-reducing ends — the only place enzymes can add or remove glucose — so the whole granule can be built or torn down in parallel.
Glycogenesis (synthesis). Incoming glucose-6-phosphate is isomerized to glucose-1-phosphate by phosphoglucomutase. UDP-glucose pyrophosphorylase then couples glucose-1-phosphate to UTP, producing the activated donor UDP-glucose and releasing pyrophosphate; hydrolysis of that pyrophosphate by inorganic pyrophosphatase makes the step effectively irreversible. Glycogen synthase, the committed and rate-limiting enzyme of synthesis, transfers the glucosyl group from UDP-glucose onto the 4-OH of a non-reducing end, forming a new α-1,4 bond and releasing UDP. Once a chain grows past about 11 residues, branching enzyme (amylo-(1,4→1,6)-transglucosylase) transfers a terminal block of ~7 glucoses to an interior position via an α-1,6 bond, seeding a new branch.
Glycogenolysis (breakdown). Glycogen phosphorylase, the rate-limiting enzyme of breakdown, cleaves the terminal α-1,4 bond by phosphorolysis — using inorganic phosphate rather than water — to release glucose-1-phosphate already carrying a phosphate. It requires pyridoxal phosphate (vitamin B6) and stops four residues short of each branch point, leaving a limit dextrin. The bifunctional debranching enzyme then acts twice: its 4-α-glucanotransferase activity relocates a block of three glucoses to a nearby chain, and its α-1,6-glucosidase activity hydrolyzes the last branch-point glucose to free glucose. Phosphoglucomutase converts glucose-1-phosphate back to glucose-6-phosphate, which enters glycolysis in muscle or, in liver, is dephosphorylated by glucose-6-phosphatase and exported to the blood.
The hormonal switch. Control is reciprocal and covalent. Glucagon (liver) and epinephrine (liver and muscle) raise cAMP and activate protein kinase A (PKA). PKA phosphorylates phosphorylase kinase, which converts phosphorylase b to active phosphorylase a; PKA also directly phosphorylates and inactivates glycogen synthase — so breakdown runs and synthesis stops. Insulin does the opposite: through the PI3K/Akt pathway it activates protein phosphatase 1 (PP1) and inhibits glycogen synthase kinase-3 (GSK-3), so synthase is dephosphorylated and switched on while phosphorylase is dephosphorylated and switched off. In muscle, two allosteric shortcuts override the hormone: a Ca²⁺ spike from contraction directly activates phosphorylase kinase through its calmodulin subunit, and rising AMP directly activates phosphorylase b — mobilizing fuel the instant the muscle fires.
Liver vs muscle glycogen
| Feature | Liver glycogen | Muscle glycogen |
|---|---|---|
| Amount stored | ~100 g (5–6% of wet weight) | ~400 g total (1–2% of wet weight) |
| Primary purpose | Buffer blood glucose for the whole body | Local ATP for contraction |
| Glucose-6-phosphatase | Present — exports free glucose | Absent — glucose-6-P trapped and burned |
| Glucagon receptor | Yes (glucagon-responsive) | No (does not respond to glucagon) |
| Epinephrine response | Yes (β-adrenergic) | Yes (β-adrenergic + Ca²⁺/AMP) |
| Glucokinase vs hexokinase | Glucokinase (high Km, unsaturated) | Hexokinase (low Km, product-inhibited) |
| Depletion window | Largely gone after 12–24 h fasting | 60–120 min of endurance exercise |
| Associated GSD | Von Gierke (I), Hers (VI) | McArdle (V), Pompe (II), Cori (III) |
Glycogenesis vs glycogenolysis
| Property | Glycogenesis (synthesis) | Glycogenolysis (breakdown) |
|---|---|---|
| Rate-limiting enzyme | Glycogen synthase | Glycogen phosphorylase |
| Bond made / broken | Forms α-1,4 (branch enzyme adds α-1,6) | Breaks α-1,4 (debrancher clears α-1,6) |
| Key substrate / product | Consumes UDP-glucose | Releases glucose-1-phosphate |
| Cofactor / primer | Glycogenin primer; UTP for activation | Pyridoxal phosphate (vitamin B6) |
| Energy cost | 2 high-energy phosphates per glucose added | No ATP spent (product pre-phosphorylated) |
| Active when | Fed state — insulin high | Fasted / exercise — glucagon or epinephrine high |
| Covalent activation | Dephosphorylated synthase (by PP1) | Phosphorylated phosphorylase a (by phosphorylase kinase) |
Common misconceptions
- "Muscle glycogen raises blood sugar." It cannot. Muscle lacks glucose-6-phosphatase, so its glucose-6-phosphate is trapped and metabolized locally. Only the liver (and, to a small degree, the kidney) can dephosphorylate glucose-6-phosphate and release free glucose into the circulation. During fasting, blood glucose is defended by liver glycogen and gluconeogenesis, never by the far larger muscle store.
- "Phosphorylase releases free glucose." It releases glucose-1-phosphate by phosphorolysis, not free glucose. Roughly 90% of residues come off as glucose-1-phosphate; only the ~8% at branch points, freed by debranching enzyme's glucosidase activity, come off as free glucose. Using phosphate instead of water saves the cell the ATP it would otherwise spend re-phosphorylating glucose.
- "Synthesis and breakdown are just the reverse of each other." They use entirely different enzymes and are never run backward through the same steps. Synthesis needs the activated donor UDP-glucose and glycogen synthase; breakdown uses inorganic phosphate and phosphorylase. Running distinct pathways is what lets the cell control them independently and avoid a wasteful futile cycle.
- "Glycogen can build itself from single glucose molecules." Glycogen synthase can only extend an existing chain of at least four glucoses — it cannot start one. Every glycogen granule is nucleated by the protein glycogenin, which auto-glucosylates a specific tyrosine to lay down the first primer, and stays buried at the core of the finished molecule.
- "Glucagon mobilizes muscle glycogen." Muscle has no glucagon receptor and is entirely deaf to it. Muscle glycogenolysis is driven instead by epinephrine (β-adrenergic → cAMP → PKA) and, more immediately, by the Ca²⁺ released during contraction and by rising AMP — both of which activate phosphorylase directly without any hormone at all.
- "Insulin only affects glucose uptake." Beyond promoting GLUT4-mediated uptake, insulin actively remodels glycogen enzymes: through Akt it inhibits GSK-3 and activates protein phosphatase 1, so glycogen synthase is dephosphorylated and switched on while phosphorylase is switched off. Storage is an active, enzyme-level decision, not a passive consequence of more glucose entering the cell.
Famous experiments and history
- The Cori couple and the Cori cycle (1929–1947). Carl and Gerty Cori, working at Washington University in St. Louis, characterized glucose-1-phosphate (the "Cori ester"), purified glycogen phosphorylase, and described the lactate-to-glucose Cori cycle linking muscle and liver. Gerty Cori became the first American woman to win a Nobel Prize in science when the couple shared the 1947 Nobel Prize in Physiology or Medicine "for their discovery of the course of the catalytic conversion of glycogen."
- Sutherland's discovery of cAMP (1957–1958). Earl Sutherland, studying how epinephrine and glucagon stimulate liver glycogen breakdown, isolated a heat-stable "second messenger" — cyclic AMP — produced at the membrane by adenylyl cyclase. This work founded the entire concept of second-messenger signaling and earned Sutherland the 1971 Nobel Prize in Physiology or Medicine.
- Krebs and Fischer on reversible phosphorylation (1955–1956). Edwin Krebs and Edmond Fischer showed that phosphorylase is switched between an inactive "b" and active "a" form by the addition and removal of a phosphate group — the first demonstration of protein phosphorylation as a regulatory switch. The principle now underlies most of cell signaling; they shared the 1992 Nobel Prize in Physiology or Medicine.
- Gerty Cori and the first molecular disease of metabolism (1952). The Coris identified the specific enzyme defect in von Gierke disease as a deficiency of glucose-6-phosphatase — one of the first times an inherited human disease was pinned to a single missing enzyme, launching the biochemical classification of the glycogen storage diseases still used today.
- McArdle's exercising forearm (1951). Brian McArdle described a patient whose muscles cramped on exertion and, tellingly, produced no rise in venous lactate during ischemic exercise — proving the muscle could not break down its own glycogen. The defect was later traced to muscle glycogen phosphorylase (myophosphorylase), defining GSD type V and its hallmark "second wind."
Frequently asked questions
What is the difference between liver and muscle glycogen?
Liver and muscle store glycogen for opposite purposes. The liver holds roughly 100 grams — about 5 to 6% of its wet weight — and treats it as a public reserve: it expresses glucose-6-phosphatase, so it can dephosphorylate glucose-6-phosphate and export free glucose to the bloodstream, buffering blood sugar between meals. Skeletal muscle holds roughly 400 grams in total but only 1 to 2% by weight, and it is a private fuel depot: muscle lacks glucose-6-phosphatase, so the glucose-6-phosphate it liberates is trapped and burned locally through glycolysis for contraction. Muscle also cannot respond to glucagon (it has no glucagon receptor), whereas the liver's phosphorylase is controlled by both glucagon and epinephrine. This division of labor is why a marathon runner can deplete muscle glycogen to exhaustion without dropping blood glucose, and why liver glycogen — not muscle — is what keeps the brain fed overnight.
How does glycogen synthase build glycogen?
Glycogenesis starts by activating glucose. Glucose-6-phosphate from hexokinase or glucokinase is isomerized to glucose-1-phosphate by phosphoglucomutase, then coupled to UDP by UDP-glucose pyrophosphorylase to make UDP-glucose — the activated donor. This step hydrolyzes the released pyrophosphate to two phosphates, which pulls the reaction forward irreversibly. Glycogen synthase then transfers the glucosyl group from UDP-glucose onto the 4-hydroxyl of the non-reducing end of a growing chain, forming an α-1,4 glycosidic bond and releasing UDP. Synthase cannot start from nothing: it needs a primer of at least a few glucose residues, which the protein glycogenin provides by auto-glucosylating a tyrosine on itself, building a short oligosaccharide that stays covalently attached at the core of every glycogen granule. Once chains reach about 11 residues, branching enzyme (amylo-(1,4→1,6)-transglucosylase) snips off a block of ~7 glucoses and reattaches it via an α-1,6 bond, creating the branch points that make glycogen soluble and fast to mobilize.
How does glycogen phosphorylase break down glycogen?
Glycogenolysis is run by glycogen phosphorylase, which performs phosphorolysis rather than hydrolysis: it uses inorganic phosphate (not water) to cleave the terminal α-1,4 bond, releasing glucose-1-phosphate directly. This is energetically clever — the product is already phosphorylated, so the cell skips the ATP it would spend to phosphorylate free glucose. Phosphorylase requires pyridoxal phosphate (vitamin B6) as a cofactor and works only on the outer α-1,4 chains, stopping four residues before each α-1,6 branch point (the limit dextrin). A single bifunctional debranching enzyme then finishes the job: its transferase activity moves a block of three glucoses to a nearby chain, and its α-1,6-glucosidase activity hydrolyzes the remaining branch glucose to free glucose. Phosphoglucomutase converts glucose-1-phosphate to glucose-6-phosphate, which enters glycolysis in muscle or is dephosphorylated for export in liver.
How do insulin, glucagon, and epinephrine control glycogen metabolism?
Control is reciprocal — the same signals that turn synthesis on turn breakdown off. In the fasted state, glucagon (in liver) and epinephrine (in liver and muscle) bind Gs-coupled receptors, raise cAMP, and activate protein kinase A. PKA phosphorylates and activates phosphorylase kinase, which phosphorylates glycogen phosphorylase (converting inactive phosphorylase b to active phosphorylase a); PKA simultaneously phosphorylates and inactivates glycogen synthase. The result is net breakdown. In the fed state, insulin acts through its receptor tyrosine kinase and the PI3K/Akt pathway to activate protein phosphatase 1 (PP1) and to inhibit glycogen synthase kinase-3 (GSK-3). PP1 dephosphorylates phosphorylase (shutting breakdown off) and dephosphorylates synthase (switching synthesis on), so the flux reverses toward storage. In muscle, contraction adds a fast layer: a rise in Ca²⁺ directly activates phosphorylase kinase through its calmodulin subunit, and AMP allosterically activates phosphorylase b — so muscle can mobilize glycogen instantly without waiting for a hormone.
What are glycogen storage diseases?
Glycogen storage diseases (GSDs) are inherited enzyme deficiencies that either block glycogen breakdown or produce abnormal glycogen, and there are at least 15 recognized types. Type I (von Gierke disease) is glucose-6-phosphatase deficiency: the liver can make glucose-6-phosphate but cannot release free glucose, causing severe fasting hypoglycemia, lactic acidosis, hepatomegaly, and hyperuricemia. Type II (Pompe disease) is a deficiency of lysosomal acid α-glucosidase (acid maltase), so glycogen accumulates inside lysosomes and destroys cardiac and skeletal muscle; it is the only GSD treated by enzyme replacement therapy. Type III (Cori/Forbes disease) is debranching enzyme deficiency, leaving limit-dextrin-like glycogen. Type V (McArdle disease) is muscle glycogen phosphorylase deficiency, causing exercise intolerance, cramps, and myoglobinuria, with the classic 'second wind' phenomenon as the body shifts to fatty acids. Type VI (Hers disease) is liver phosphorylase deficiency, a milder cause of hepatomegaly and mild hypoglycemia.
Why does the body store glucose as branched glycogen instead of free glucose?
Storing tens of thousands of glucose molecules as one branched polymer solves two problems at once — osmotic pressure and speed. Free glucose is osmotically active: dissolving the ~100 g of glucose held in liver glycogen as individual molecules would create a solute concentration high enough to draw catastrophic amounts of water into the cell and lyse it. Polymerizing them into a single glycogen molecule reduces the effective particle count by more than a thousandfold, so the osmotic cost nearly vanishes. Branching solves the speed problem: with an α-1,6 branch roughly every 8 to 12 residues, a single glycogen granule (a beta particle of ~55,000 glucose units, or an assembled alpha rosette) exposes a huge number of non-reducing ends simultaneously. Because both glycogen synthase and glycogen phosphorylase act only at non-reducing ends, many enzymes can build or dismantle the same molecule in parallel, so glucose can be mobilized in seconds to meet a sudden demand — exactly what a sprinting muscle or a hypoglycemic brain requires.
How long does glycogen last during fasting or exercise?
It depends on the demand and the depot. Liver glycogen — about 100 grams, holding roughly 400 kilocalories — is the body's short-term blood-glucose buffer and is largely depleted after 12 to 24 hours of fasting, after which gluconeogenesis takes over as the main glucose source. Muscle glycogen — about 400 grams — is reserved for the muscle itself. During intense endurance exercise (running or cycling at 65 to 85% of VO₂ max), muscle glycogen is the dominant fuel and typically runs out after 60 to 120 minutes; that depletion is the 'hitting the wall' or 'bonking' that marathon runners feel around the 30-kilometer mark. Carbohydrate loading before an event can push muscle glycogen stores roughly 50 to 100% higher than baseline, extending the time to exhaustion, which is why endurance athletes deliberately over-fill these stores in the days before a race.